Work

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.3000

Authors: Roy S. Herbst, Michael S. Gordon, Gregg Daniel Fine, Jeffrey Alan Sosman, Jean-Charles Soria, Omid Hamid, John D. Powderly, Howard A. Burris, Ahmad Mokatrin, Marcin Kowanetz, Maya Leabman, Maria Anderson, Daniel S. Chen, F. Stephen Hodi

Institutions: Yale University, Pinnacle Oncology Hematology, Genentech, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Institut Gustave Roussy, Angeles Clinic and Research Institute, Carolina BioOncology Institute, Sarah Cannon, Dana-Farber Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1829526068

Cites:

Cited by: 191

Related to: 10